Asian Spectator


The Times

.

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

New commercialisation agreement builds on existing partnership with Zuellig Pharma

SINGAPORE - Media OutReach Newswire - 16 January 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV® Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-libraryagen bolatelegram下载tipobetGanobetzlibrary.jojobetสล็อตสล็อตgrandpashabetstakejojobetTotalSportStreamEasthitbet girişroyalbet girişjojobetjojobetmarsbahisvipparkGalabetDizipaljojobetStreamEastgrandpashabetvdcasinosuperbetin